Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study

PURPOSE: During treatment with tyrosine kinase inhibitors, such as sunitinib, patients experience treatment and/or disease-related symptoms. Although application of patient-reported outcome measures (PROMs) enhances early recognition of symptoms, early clinical trials are focused on symptom severity...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Support Care Cancer
Asıl Yazarlar: Koldenhof, J. J., Lankheet, N. A. G., Steeghs, N., Teunissen, S. C. C. M., Witteveen, P. O.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2018
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6018583/
https://ncbi.nlm.nih.gov/pubmed/29464389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-018-4075-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller